PT3107914T - Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos - Google Patents

Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos

Info

Publication number
PT3107914T
PT3107914T PT15706282T PT15706282T PT3107914T PT 3107914 T PT3107914 T PT 3107914T PT 15706282 T PT15706282 T PT 15706282T PT 15706282 T PT15706282 T PT 15706282T PT 3107914 T PT3107914 T PT 3107914T
Authority
PT
Portugal
Prior art keywords
pyrazolo
pyrimidine
therapeutic use
diamine compounds
cdk inhibitors
Prior art date
Application number
PT15706282T
Other languages
English (en)
Portuguese (pt)
Inventor
Bondke Alexander
kroll Sebastian
Barrett Anthony
Fuchter Matthew
Slafer Brian
Ali Simak
Coombes Charles
Patrick Snyder James
Original Assignee
Univ Emory
Cancer Research Tech Ltd
Ip2Ipo Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Cancer Research Tech Ltd, Ip2Ipo Innovations Ltd filed Critical Univ Emory
Publication of PT3107914T publication Critical patent/PT3107914T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT15706282T 2014-02-21 2015-02-20 Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos PT3107914T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use

Publications (1)

Publication Number Publication Date
PT3107914T true PT3107914T (pt) 2019-05-20

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15706282T PT3107914T (pt) 2014-02-21 2015-02-20 Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos

Country Status (23)

Country Link
US (4) US9932344B2 (cg-RX-API-DMAC7.html)
EP (1) EP3107914B8 (cg-RX-API-DMAC7.html)
JP (1) JP6498212B2 (cg-RX-API-DMAC7.html)
CN (1) CN106103445B (cg-RX-API-DMAC7.html)
AU (1) AU2015220560B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016018633B1 (cg-RX-API-DMAC7.html)
CA (1) CA2939786C (cg-RX-API-DMAC7.html)
CY (1) CY1121588T1 (cg-RX-API-DMAC7.html)
DK (1) DK3107914T3 (cg-RX-API-DMAC7.html)
ES (1) ES2721268T3 (cg-RX-API-DMAC7.html)
GB (1) GB201403093D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20190685T1 (cg-RX-API-DMAC7.html)
HU (1) HUE043122T2 (cg-RX-API-DMAC7.html)
LT (1) LT3107914T (cg-RX-API-DMAC7.html)
ME (1) ME03427B (cg-RX-API-DMAC7.html)
NZ (1) NZ724323A (cg-RX-API-DMAC7.html)
PL (1) PL3107914T3 (cg-RX-API-DMAC7.html)
PT (1) PT3107914T (cg-RX-API-DMAC7.html)
RS (1) RS58704B1 (cg-RX-API-DMAC7.html)
SI (1) SI3107914T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900266T1 (cg-RX-API-DMAC7.html)
TR (1) TR201905647T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015124941A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2015337607B2 (en) 2014-10-31 2020-04-09 Ube Corporation Substituted dihydropyrrolopyrazole compound
BR112017012588B8 (pt) 2014-12-17 2024-02-15 King S College London Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
CN113563342A (zh) * 2015-02-13 2021-10-29 达纳-法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
RU2765718C1 (ru) 2015-06-15 2022-02-02 Убе Индастриз, Лтд. Замещенное производное дигидропирролопиразола
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
KR102411150B1 (ko) 2016-08-31 2022-06-21 아지오스 파마슈티컬스 아이엔씨. 세포 대사 과정의 억제제
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Cdk8/19阻害薬としての新規ヘテロ環式化合物
US20200197392A1 (en) * 2017-08-15 2020-06-25 The Brigham & Women's Hospital, Inc. Compositions and methods for treating tuberous sclerosis complex
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
CA3095880A1 (en) * 2018-04-11 2019-10-17 Qurient Co., Ltd. Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
WO2020006497A1 (en) 2018-06-29 2020-01-02 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
EP3873911A4 (en) 2018-10-30 2022-06-22 Kronos Bio, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF MODULATING CDK9 ACTIVITY
JP7530297B2 (ja) 2018-11-14 2024-08-07 Ube株式会社 ジヒドロピロロピラゾール誘導体
CN109860354B (zh) * 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
US20220144841A1 (en) * 2019-03-13 2022-05-12 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
WO2021003517A1 (en) * 2019-07-10 2021-01-14 Aucentra Therapeutics Pty Ltd Derivatives of 4-(imidazo[l,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin- 2-amine as therapeutic agents
IL292519A (en) * 2019-10-29 2022-06-01 Syros Pharmaceuticals Inc Methods for treating cancer in patients identified with a biomarker with cyclin-dependent kinase 7 (cdk7) inhibitors
GB201918541D0 (en) * 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2021176045A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
JP7657943B2 (ja) * 2021-01-22 2025-04-07 上海海雁医薬科技有限公司 置換ピラゾロ[1,5-a]ピリミジン-7-アミン誘導体、その組成物及び医薬上の使用
WO2022236058A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
JP2024543136A (ja) * 2021-11-24 2024-11-19 クロノス バイオ インコーポレイテッド (1S,3S)-N1-(5-(ペンタン-3-イル)ピラゾロ[1,5-a]ピリミジン-7-イル)シクロペンタン-1,3-ジアミンの多形性形態および塩形態
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases
WO2024174949A1 (zh) * 2023-02-20 2024-08-29 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025006569A1 (en) 2023-06-27 2025-01-02 Arvinas Operations, Inc. Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer
WO2025057087A1 (en) 2023-09-11 2025-03-20 Assia Chemical Industries Ltd. Solid state forms of samuraciclib
WO2025208104A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2025208097A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2457201A (en) 1999-12-28 2001-07-09 Bristol-Myers Squibb Company Cytokine, especially tnf-alpha, inhibitors
ATE469903T1 (de) 2002-09-04 2010-06-15 Schering Corp Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
CA2513684A1 (en) 2003-01-31 2004-08-19 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
BRPI0407834A (pt) 2003-02-28 2006-02-14 Teijin Pharma Ltd composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
TWI421078B (zh) * 2005-10-06 2014-01-01 Merck Sharp & Dohme 關卡激酶抑制劑及其用途
JP2010529140A (ja) * 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
PT3409278T (pt) * 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Also Published As

Publication number Publication date
BR112016018633A2 (cg-RX-API-DMAC7.html) 2017-08-08
EP3107914B1 (en) 2019-01-30
TR201905647T4 (tr) 2019-05-21
CY1121588T1 (el) 2020-05-29
CA2939786C (en) 2022-03-08
US10927119B2 (en) 2021-02-23
ES2721268T3 (es) 2019-07-30
JP2017506250A (ja) 2017-03-02
US9932344B2 (en) 2018-04-03
HUE043122T2 (hu) 2019-08-28
NZ724323A (en) 2022-02-25
BR112016018633B1 (pt) 2022-08-30
PL3107914T3 (pl) 2019-09-30
US20160362410A1 (en) 2016-12-15
SMT201900266T1 (it) 2019-07-11
JP6498212B2 (ja) 2019-04-10
DK3107914T3 (en) 2019-04-29
LT3107914T (lt) 2019-05-27
SI3107914T1 (sl) 2019-05-31
ME03427B (me) 2020-01-20
AU2015220560A1 (en) 2016-10-06
HRP20190685T1 (hr) 2019-06-14
EP3107914A1 (en) 2016-12-28
US11566029B2 (en) 2023-01-31
RS58704B1 (sr) 2019-06-28
WO2015124941A1 (en) 2015-08-27
AU2015220560B2 (en) 2019-05-16
US10414772B2 (en) 2019-09-17
GB201403093D0 (en) 2014-04-09
US20200055862A1 (en) 2020-02-20
EP3107914B8 (en) 2019-07-17
US20210253583A1 (en) 2021-08-19
CN106103445B (zh) 2019-08-09
CN106103445A (zh) 2016-11-09
US20180273540A1 (en) 2018-09-27
CA2939786A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
PT3107914T (pt) Compostos de pirazolo[1,5-a]pirimidina-5,7-diamina como inibidores de cdk e utilização terapêutica dos mesmos
IL260923B (en) History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1245247A1 (zh) 溴结构域的抑制剂
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
IL247947B (en) 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors
ZA201800485B (en) Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
ZA201701207B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
IL258070B (en) Cyclic ether history of pyrazolo[5,1–a]pyrimidine-3-carboxamide
IL253427A0 (en) The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose